Table 6 |
||||
|
Indirect comparison results: duloxetine vs. gabapentin. |
||||
|
Outcome |
Indirect treatment comparison (δ) Mean (median) |
95% CI for δ |
Between-study variance (τ 2) Mean (median) |
95% CI for τ2 |
|
|
||||
|
Efficacy |
||||
|
Reduction in 24-hour pain intensity |
0.270 (0.266) |
(-0.469; 1.022) |
0.041 (0.013) |
(0.001; 0.247) |
|
|
||||
|
Tolerability |
||||
|
Premature study discontinuation due to: |
||||
|
- Lack of efficacy |
0.067 (0.065) |
(-1.988; 2.116) |
0.177 (0.028) |
(0.001; 1.281) |
|
- Adverse events |
0.841 (0.835) |
(-0.348; 2.065) |
0.062 (0.015) |
(0.001; 0.406) |
|
- Other |
-0.245 (-0.252) |
(-1.527; 1.075) |
0.060 (0.015) |
(0.001; 0.386) |
|
Diarrhoea |
-0.244 (-0.246) |
(-1.645; 1.164) |
0.273 (0.051) |
(0.001; 1.825) |
|
Dizziness |
-1.044 (-1.054) |
(-2.258; 0.183) |
0.090 (0.021) |
(0.001; 0.590) |
|
Headache |
-0.689 (-0.697) |
(-1.986; 0.638) |
0.053 (0.013) |
(0.001; 0.348) |
|
Nausea |
0.704 (0.700) |
(-0.567; 2.021) |
0.085 (0.022) |
(0.001; 0.529) |
|
Somnolence |
-0.101 (-0.107) |
(-1.249; 1.078) |
0.080 (0.016) |
(0.001; 0.545) |
|
|
||||
|
Note: δ is the mean difference in treatment effect between DLX and each comparator. τ2 is between-study heterogeneity. |
||||
|
Quilici et al. BMC Neurology 2009 9:6 doi:10.1186/1471-2377-9-6 |
||||
